PRDX6

Across TCGA pan-cancer cohorts, PRDX6 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRDX6 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRDX6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRDX6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where PRDX6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.164	0.845	.006	16	view →
CCRCC	DFS	Median	All	1.000	0.729	.017	10	view →
PDAC	DFS	Tertile	All	0.849	0.721	.012	8	view →
UCEC	OS	Quartile	II,III,IV	0.332	1.000	.030	4	view →
HNSC	DFS	Median	IV	0.920	1.000	.028	2	view →
GBM	DFS	Median	All	0.673	0.815	.045	1	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRDX6–LUAD (OS)

Open the LUAD breakdown →